Black checkmark with a sparkle and a curved line underneath on a white background.
Company

Serina Therapeutics, Inc.

Ticker
SER
Sector
Industry
Report date
November 14, 2026
Valye AI Score

96

Very high visibility
Recent developments
Recent developments summary

Recent developments highlight Serina's clinical progress with SER-252, governance changes, financing activities, and regulatory compliance.

Recent developments:
  • Serina concluded dosing in its Phase 1b trial for Parkinson's therapy SER-252 and appointed Simon to its board in July 2026, reflecting clinical and governance progress [N1].
  • The NYSE American accepted Serina's continued listing compliance plan in April 2026, following a deficiency notification regarding shareholders' equity earlier in January 2026 [N3][N5].
  • Serina secured $30 million in financing in March 2026 to advance its Parkinson's trial, supporting its clinical development efforts [N1].
  • The company opened registration for a CEO presentation and Q&A webinar event in February 2026, indicating investor engagement activities [N4].
  • Serina appointed Dr. Stephen Brannan to its board in May 2025 to enhance CNS therapeutic development capabilities [N8].
  • The company announced a strategic partnership with Gannet BioChem to support SER-252 development for Parkinson's disease in July 2026 [N1].
Overview

Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing therapies for Parkinson's disease and other central nervous system disorders. Its lead candidate, SER-252, is in early-stage clinical development, having received FDA clearance for its investigational new drug application in January 2026. The company initiated and completed dosing in a Phase 1b registrational trial for SER-252 in advanced Parkinson's disease patients. Serina has strategic partnerships and has strengthened its leadership team to support CNS therapeutic development. The company is listed on the NYSE American and operates under a compliance plan following a deficiency notification related to shareholders' equity. As of September 30, 2026, Serina held $19.4 million in cash and equivalents and reported a net loss of $7.9 million for the quarter, reflecting ongoing investment in clinical programs.

Executive summary

Financial figures (if any) are summarized from the latest available SEC filings and are provided for informational purposes only — not financial advice. Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing SER-252 for Parkinson's disease. The company reported cash and cash equivalents of $19.4 million and total stockholders' equity of $13.9 million as of September 30, 2026, with a net loss of $7.9 million for the quarter. Serina operates under an accepted NYSE American continued listing compliance plan and has completed a $30 million financing to advance its Parkinson's trial. The company faces risks related to ownership concentration, dilution, clinical development uncertainties, and ongoing capital needs.

Scenarios for SER

Bull case model:

Serina's advancement of SER-252 through Phase 1b clinical trials and FDA clearance of its IND application demonstrate progress in addressing Parkinson's disease, a large market with unmet needs. The company's successful $30 million financing and strategic partnerships provide resources and support for continued development. Strengthened leadership and board appointments focused on CNS therapeutics may enhance execution capabilities. Maintaining NYSE American listing compliance supports market access and investor confidence.

Bear case model:

Serina faces substantial risks including its early-stage clinical development status, with inherent uncertainties in trial outcomes and regulatory approvals. The company has a history of operating losses and substantial doubt about its ability to continue as a going concern without additional financing. Concentration of ownership by a few investors may limit broader stockholder influence and pose governance risks. Potential dilution from outstanding warrants and equity issuances could impact shareholder value. Failure to maintain NYSE American listing compliance could adversely affect liquidity and capital raising.

Moat:

Serina Therapeutics' moat is primarily based on its proprietary clinical-stage therapeutic candidate SER-252 targeting Parkinson's disease, a significant unmet medical need. The company's strategic partnerships and specialized leadership in CNS therapeutics contribute to its development capabilities. However, as a clinical-stage biopharmaceutical company without approved products, its competitive advantage depends on successful clinical development, regulatory approvals, and intellectual property protection. The concentration of ownership and governance structure may influence strategic decisions but do not constitute a moat in the traditional sense.

Risks overview
Risks summary
The most significant risks include the company's early-stage clinical development status with uncertain outcomes, substantial doubt about its ability to continue as a going concern without additional financing, and concentration of ownership that may affect governance and stockholder influence.
Risks details:

• Concentration of Ownership and Governance Risks: Dr. Gregory H. Bailey and Juvenescence collectively control a majority of the company's common stock, enabling significant influence over corporate decisions, which may not align with all stockholders' interests.
• Capital and Liquidity Risks: The company has a history of operating losses and substantial doubt about its ability to continue as a going concern without additional financing. Future capital raises may cause dilution and affect stock price.
• Clinical Development Risks: SER-252 is in early-stage clinical trials with inherent uncertainties in timing, enrollment, outcomes, and regulatory approvals that could impact the company's business prospects.
• Listing Compliance Risks: Serina operates under an accepted NYSE American continued listing compliance plan. Failure to maintain compliance could lead to delisting, reducing stock liquidity and capital access.
• Dilution Risks: Outstanding warrants, pre-funded warrants, and equity-linked securities could result in substantial dilution to existing stockholders upon exercise or issuance.

FINAL FORECAST FOR SER

Final take one line
Serina Therapeutics is a clinical-stage biopharmaceutical company with high visibility into its Parkinson's therapy development, governance, and financial condition, facing typical early-stage biotech risks including clinical uncertainty and capital needs.
Final take 12 to 24 month view

Business trends: Advancement of SER-252 through early-stage clinical trials with strategic partnerships and governance strengthening.
Execution milestones: Completion of Phase 1b dosing, maintenance of NYSE American listing compliance, and securing financing to support clinical programs.
Key risks: Clinical development uncertainties, substantial doubt about going concern status without additional financing, ownership concentration affecting governance, and potential dilution from equity issuances.

Valye AI Visibility Research Score

Very high visibility

Visibility score reflects the breadth and consistency of available disclosure across SEC filings, recent public reporting, and baseline business context (research-only; not investment advice).

96
LLM visibility overview
LLM Visibility known facts
  • Serina Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for Parkinson's disease and other CNS disorders.
  • The lead product candidate is SER-252, which is in early-stage clinical development for advanced Parkinson's disease.
  • The FDA cleared the investigational new drug application for SER-252 in January 2026.
  • Serina initiated and dosed the first patient in a Phase 1b registrational clinical trial of SER-252 in February 2026.
  • The company concluded dosing in the Phase 1b trial as of July 2026.
  • Serina has appointed new board members including Simon and Dr. Stephen Brannan to enhance CNS therapeutic development and governance.
  • The company has a strategic partnership with Gannet BioChem to support SER-252 development.
  • Serina completed a $30 million financing in March 2026 to advance its Parkinson's trial.
  • The company operates under an accepted NYSE American continued listing compliance plan as of April 2026, following a deficiency notification in January 2026 regarding shareholders' equity.
  • As of September 30, 2026, Serina had cash and cash equivalents of approximately $19.4 million and total stockholders' equity of approximately $13.9 million.
  • The company reported a net loss of approximately $7.9 million for the quarter ended September 30, 2026, with basic and diluted EPS of -$0.31.
  • Liquidity ratios as of September 30, 2026, include a current ratio of 4.62 and a cash ratio of 4.28, indicating a strong short-term liquidity position.
  • The March 2026 private investment in public equity (PIPE) transaction significantly changed the capital structure, including the conversion of Series A Preferred Stock and issuance of pre-funded warrants.
  • Dr. Gregory H. Bailey, a board member and Co-Chairman, beneficially owns approximately 44% of the common stock as of November 2026, and Juvenescence owns approximately 16%, together controlling a majority of voting power.
  • The company faces risks related to potential dilution from outstanding warrants and equity issuances, concentration of ownership, and substantial doubt about its ability to continue as a going concern without additional financing.
  • Serina's business and financial condition are subject to risks including clinical trial uncertainties, regulatory approvals, and capital raising challenges.
  • The company has disclosed that its existing cash is not sufficient to fund operations for the next 12 months following the September 2026 interim financial statements.
  • Serina's governance includes an Executive Chairman and board members with ties to Juvenescence, which may influence strategic decisions and stockholder voting outcomes.
Sources
Sources - Context summary

Generated 2026-11-15

Sources - Earning calls
Sources - Other context
Sources - SEC Filings
  • S1 | 2026-03-27 | 10-K/A
  • S2 | 2026-11-12 | 10-Q
Sources - News headlines
  • N1 | 2026-07-23 | www.nasdaq.com | Serina Appoints Simon To Board; Concludes Dosing In Phase 1b For Parkinson's Therapy SER-252 | https://www.nasdaq.com/articles/serina-appoints-simon-board-concludes-dosing-phase-1b-parkinsons-therapy-ser-252
  • N2 | 2026-07-02 | www.nasdaq.com | Weekly Buzz: VRTX, APTX Gain FDA Nod; UNCY Disappoints; Ipsen Opens Wallet; VTGN Misses Goal | https://www.nasdaq.com/articles/weekly-buzz-vrtx-aptx-gain-fda-nod-uncy-disappoints-ipsen-opens-wallet-vtgn-misses-goal
  • N3 | 2026-04-06 | www.nasdaq.com | NYSE Accepts Serina Therapeutics Continued Listing Compliance Plan | https://www.nasdaq.com/articles/nyse-accepts-serina-therapeutics-continued-listing-compliance-plan
  • N4 | 2026-02-03 | www.globenewswire.com | Registration Is Now Open For Tribe Public’s CEO Presentation and Q&A Webinar Event | https://globenewswire.com/news-release/2026/02/03/3230824/0/en/Registration-Is-Now-Open-For-Tribe-Public-s-CEO-Presentation-and-Q-A-Webinar-Event.html
  • N5 | 2026-01-15 | www.globenewswire.com | Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity | https://www.globenewswire.com/news-release/2026/01/15/3220012/0/en/Serina-Therapeutics-Receives-NYSE-Deficiency-Notification-Regarding-Shareholders-Equity.html
  • N6 | 2025-06-23 | www.nasdaq.com | Serina Therapeutics to Present Next-Gen Approach for Parkinson’s Care at FORCE Family Office Webinar | https://www.nasdaq.com/articles/serina-therapeutics-present-next-gen-approach-parkinsons-care-force-family-office-webinar
  • N7 | 2025-06-17 | www.nasdaq.com | Serina Therapeutics Congratulates Juvenescence on Securing $150 Million Series B Financing and Strategic Alliance with M42 | https://www.nasdaq.com/articles/serina-therapeutics-congratulates-juvenescence-securing-150-million-series-b-financing-and
  • N8 | 2025-05-22 | www.nasdaq.com | Serina Therapeutics Appoints Dr. Stephen Brannan to Board of Directors to Enhance CNS Therapeutic Development | https://www.nasdaq.com/articles/serina-therapeutics-appoints-dr-stephen-brannan-board-directors-enhance-cns-therapeutic
Important legal disclaimer

This material is for informational purposes only and does not constitute investment, financial, legal or tax advice, or an offer or solicitation to buy or sell any security. The Valye AI Score is a model-based estimate derived from public information and is subject to change without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information herein. Past performance is not indicative of future results. Investors should conduct their own research and consult a qualified financial adviser before making any investment decisions.

Blue logo with a stylized checkmark and star above the blue text 'VALYE' on a black background.

Generated by Valye SEC Pipeline Engine